In accordance with clause 30 of the ABPI Code of Practice, the Mitsubishi Tanabe Pharma Group will disclose any engagements and interactions with members of the public (MoPs) including journalists and patients on this page annually.
2023 Transfers of Value
Interactions with Member’s of the Public in 2023 | |||
The methodology applied in preparing and collating these figures is available here in English* | |||
MoP Details | Funding | Country | Description of Interaction |
3 Patients | GBP 237.24 | United Kingdom | Three Patients were reimbursed for out of pocket expenses to travel to clinical trial sites. |
Terms and Privacy
Contact Us
Mitsubishi TANABE Pharma Europe Ltd
Dashwood House
69 Old Broad Street
London
EC2M 1QS
United Kingdom